Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies

NCT02347228 is registered in ClinicalTrials.gov with Oneness Biotech Co., Ltd. as lead sponsor.

NCT NCT02347228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02347228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
Lead sponsor
Oneness Biotech Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
August 28, 2020
Completion date
November 22, 2024
Enrollment
21 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies